<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) are clonal myeloid disorders characterized by bone marrow cell <z:mpath ids='MPATH_589'>dysplasia</z:mpath> and ineffective hematopoiesis leading to peripheral refractory cytopenias </plain></SENT>
<SENT sid="1" pm="."><plain>The course of the disease ranges from a <z:hpo ids='HP_0011010'>chronic</z:hpo> status with progressively <z:mp ids='MP_0001606'>impaired hematopoiesis</z:mp> to rapid evolution to <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) </plain></SENT>
<SENT sid="2" pm="."><plain>A panel of continuous malignant hematopoietic cell lines has been established from the whole spectrum of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> variants and also from the different stages of the diseases, namely from the <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> phase or the overt <z:hpo ids='HP_0001909'>leukemia</z:hpo> post-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> phase </plain></SENT>
<SENT sid="3" pm="."><plain>Ten cell lines were derived from the various <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> subtypes; 17 cell lines were established from patients with <z:hpo ids='HP_0001909'>leukemia</z:hpo> (mainly <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) post-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>While most cell lines display myelocytic, monocytic or erythroid features, some cell lines carry lymphoid characteristics (precursor B-cell, B-cell, or T-cell), With regard to these lymphoid <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>-derived cell lines, more detailed authentication (prove of derivation from the assumed patient) and verification (prove of the malignant nature of the cell line and derivation from the assumed neoplastic cells) are required to validate the cell lines as true in vitro representatives of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> and to exclude any cross-contamination with other cells or immortalization of <z:mpath ids='MPATH_458'>normal</z:mpath> bystander cells </plain></SENT>
<SENT sid="5" pm="."><plain>On the other hand, lymphoid <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>-derived cell lines may attest to the clonal nature of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> which may afflict progenitor cells giving rise to lymphoid or myelomonocytoid cells </plain></SENT>
<SENT sid="6" pm="."><plain>Many of the <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>-derived cell lines carry cytogenetic and molecular genetic abnormalities typically associated with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>: gain or loss of <z:hpo ids='HP_0000001'>all</z:hpo> or parts of chromosomes 5, 7, 8 and 20 (-5/5q-, -7/7q-, + 8, 20q-); alterations of oncogenes and <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> suppressor genes (IRF-1, p15, p16, p53, <z:mp ids='MP_0011356'>RAS</z:mp>, RB) </plain></SENT>
<SENT sid="7" pm="."><plain>In summary, the present panel of cell lines provides continuously growing cells and thus unlimited cell material for use as in vitro paradigms covering the whole spectrum of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>-related hematopoetic <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> </plain></SENT>
<SENT sid="8" pm="."><plain>Properly authenticated and verified <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>-derived cell lines which should be made freely available will represent important research tools for the study of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> biology </plain></SENT>
</text></document>